Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
a study on Multiple Myeloma
Relapsed/Refractory Multiple Myeloma Multiple Myeloma Chimeric Antigen Receptor T-Cell (CART-T) therapy Transcription Activator-Like Effector Nuclease (TALEN) Allogeneic Neoplasms, Plasma Cell UCARTCS1A
Lead Scientist at UCSF
- Nina Shah
Dr. Nina Shah is a hematologist who specializes in the treatment of multiple myeloma, a type of cancer affecting the blood marrow. She treats patients at the Hematology and Blood Marrow and Transplant Clinic. Nina received a bachelor’s degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine.
- accepting new patients
- Start Date
- Completion Date
- Cellectis S.A.
- Phase 1 Multiple Myeloma Research Study
- Study Type
- Expecting 18 study participants
- Last Updated